Teva Shared Data From Ongoing Phase 1b Study Of TEV-’408 Showing Improvements In Skin Pigmentation In Active Or Stable Non-Segmental Vitiligo Patients; Plans To Advance TEV-’408 Into Phase 2b Study In Vitiligo In Q4 2026

Loading news article.

Teva Shared Data From Ongoing Phase 1b Study Of TEV-’408 Showing Improvements In Skin Pigmentation In Active Or Stable Non-Segmental Vitiligo Patients; Plans To Advance TEV-’408 Into Phase 2b Study In Vitiligo In Q4 2026 | WAPE

Teva Shared Data From Ongoing Phase 1b Study Of TEV-’408 Showing Improvements In Skin Pigmentation In Active Or Stable Non-Segmental Vitiligo Patients; Plans To Advance TEV-’408 Into Phase 2b Study In Vitiligo In Q4 2026

Article summary

Related companies

Comments —